Patient portrayal. Individual results may vary.

Diagnostic Criteria & Patient Profile

Patient portrayal

Diagnostic criteria for MDD include emotional, physical, and cognitive symptoms17

Patient portrayal

Adapted from DSM-5®

To be diagnosed with MDD, a patient must have 5 or more of the following symptoms nearly every day* during the same 2‑week period and represent a change from previous functioning. At least 1 symptom must be either depressed mood or loss of interest/pleasure.

Patient may tell you about—and may show you—their symptoms.

1. Depressed mood most of the day

2. Loss of interest/pleasure in almost all activities most of the day

3. Significant change in weight or appetite

4. Insomnia or hypersomnia

5. Psychomotor agitation/retardation

6. Loss of energy or fatigue

7. Feelings of worthlessness or excessive or inappropriate guilt

8. Difficulty concentrating or indecisiveness

9. Recurrent suicidal thoughts or actions or recurrent thoughts of death


Do not include symptoms attributable to another medical condition.

  • Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
  • Depressive episode is not attributable to the physiological effects of a substance or to another medical condition
  • Depressive episode is not better explained by other psychotic, delusional, or other specified or unspecified schizophrenia spectrum disorders
  • Patient has never had a manic or a hypomanic episode

Diagnosis should be based on a complete history and evaluation of the patient. View printable PHQ-9 screener.

*”Nearly every day” does not apply to symptom 3 (weight gain) and symptom 9.17

These are not the complete diagnostic criteria. DSM-5 is a registered trademark of the American Psychiatric Association.


Sarah, 45 Married | Project manager | 2 active children

Patient portrayal quote: "I'm ready to work with my doctor to find a treatment that's right for me. It's time for a different game plan."

Sarah is struggling with multiple symptoms beyond sadness, including loss of interest, difficulty concentrating, low energy, and excessive guilt.

Patient’s concerns:

  • No longer interested in any hobbies
  • Struggles with thinking and concentrating
  • Too tried to plan family activities

Other considerations:

  • Seeing a therapist for over 2 years
  • Family and colleagues have noticed she is still struggling

Not a complete list of symptoms. Having these symptoms does not necessarily mean a patient has MDD. Diagnosis should be based on full DSM-5® diagnostic criteria for MDD. Patients should be individually assessed for MDD with appropriate evaluation, management, and follow-up. Medication may not be appropriate for all patients with MDD. Individual results may vary.

DSM-5 is a registered trademark of the American Psychiatric Association.

Patient portrayal quote: "I'm ready to work with my doctor to find a treatment that's right for me. It's time for a different game plan."

Leaving TRINTELLIXHCP.COM

By clicking “Continue,” you will be leaving a Takeda and Lundbeck controlled website for a third-party website.

Please note that neither Takeda nor Lundbeck is responsible or liable for any third-party website, and the website may not be appropriate for all audiences.

  1. Trintellix (vortioxetine) prescribing information. Takeda Pharmaceuticals.
  2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. Int J Neuropsychopharmacol. 2012;15(5):589‑600.
  3. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. J Clin Psychiatry. 2012;73(7):953‑959.
  4. Boulenger J-P, Loft H, Olsen CK. Int Clin Psychopharmacol. 2014;29(3):138‑149.
  5. Mahableshwarkar AR, Jacobsen P, Chen Y, Serenko M, Trivedi MH. Psychopharmacology (Berl). 2015;232(12):2061‑2070.
  6. Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. J Clin Psychiatry. 2015;76(5):575‑582.
  7. Katona C, Hansen T, Olsen CK. Int Clin Psychopharmacol. 2012;27(4):215‑223.
  8. Costa SL, Genova HM, DeLuca J, Chiaravalloti ND. Mult Scler. 2017;23(6):772‑789.
  9. McIntyre RS, Lophaven S, Olsen CK. Int J Neuropsychopharmacol. 2014;17(10):1557‑1567.
  10. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. Neuropsychopharmacology. 2015;40(8):2025‑2037.
  11. Data on file. Takeda Pharmaceuticals.
  12. Data on file. Lundbeck.
  13. FDA updates Trintellix® (vortioxetine) label to include data showing improvement in processing speed, an important aspect of cognitive function in acute Major Depressive Disorder (MDD). News release. GlobeNewswire. May 2, 2018.
  14. Boulenger J-P, Loft H, Florea I. J Psychopharmacol. 2012;26(11):1408‑1416.
  15. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. J Sex Med. 2015;12(10):2036‑2048.
  16. Kambeitz JP, Howes OD. J Affect Disord. 2015;186:358-366.
  17. American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5®). Arlington, VA: American Psychiatric Association; 2013:155‑188.